Lia Haynes Smith

Dr. Lia Haynes Smith


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLia Haynes Smith
Lia Haynes Smith
HCHayat Caidi
Hayat Caidi
GRGertrud U. Radu
Gertrud U. Radu
CMCongrong Miao
Congrong Miao
JHJennifer L. Harcourt
Jennifer L. Harcourt
LALarry J. Anderson
Larry J. Anderson
Because the G protein of respiratory syncytial virus (RSV) has a CX3C chemokine motif that has been associated with the ability of RSV G protein to m

1 May 2009 in Journal of General Virology
Verified
Journal Article
Open access
CMCongrong Miao
Congrong Miao
GRGertrud U. Radu
Gertrud U. Radu
HCHayat Caidi
Hayat Caidi
Ralph TrippRalph Tripp
Ralph Tripp
LALarry J. Anderson
Larry J. Anderson
LSLia Haynes Smith
Lia Haynes Smith
Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-γ) production in the lungs of RSV-infected mice. Its F(ab′)2 component only mediates decreased leukocyte trafficking and IFN-γ production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.

15 September 2010 in Journal of Virology
Verified
Journal Article
Open access
PDF file
GRGertrud U. Radu
Gertrud U. Radu
HCHayat Caidi
Hayat Caidi
CMCongrong Miao
Congrong Miao
Ralph TrippRalph Tripp
Ralph Tripp
LALarry J. Anderson
Larry J. Anderson
LSLia Haynes Smith
Lia Haynes Smith
We examined whether prophylactically administered anti-respiratory syncytial virus (anti-RSV) G monoclonal antibody (MAb) would decrease the pulmonary inflammation associated with primary RSV infection and formalin-inactivated RSV (FI-RSV)-enhanced disease in mice. MAb 131-2G administration 1 day prior to primary infection reduced the pulmonary inflammatory response and the level of RSV replication. Further, intact or F(ab′) 2 forms of MAb 131-2G administered 1 day prior to infection in FI-RSV-vaccinated mice reduced enhanced inflammation and disease. This study shows that an anti-RSV G protein MAb might provide prophylaxis against both primary infection and FI-RSV-associated enhanced disease. It is possible that antibodies with similar reactivities might prevent enhanced disease and improve the safety of nonlive virus vaccines.

21 November 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLia Haynes Smith
Lia Haynes Smith
Respiratory syncytial virus (RSV) is a respiratory tract pathogen that causes significant morbidity and mortality in children aged <5 years (most disease occurs at age <1 year) and is a major public health burden worldwide. More than 90% of children are infected at least once with RSV before the age of 2 years [1–3]. RSV accounts for approximately 70% of hospitalizations due to bronchiolitis [1, 4]. In the United States alone, the estimated healthcare costs associated with RSV hospitalizations exceed $950 million, making it a significant economic burden [5]. Further, the RSV burden is disproportionately greater in children aged <5 years living in developing countries [3]. RSV infection does not confer long-term protection, as reinfections occur throughout life, which poses a significant disease risk in individuals with cardiopulmonary disease, immunocompromised patients, and the elderly [7]. In the elderly, complications of RSV infection often result from exacerbation of underlying pulmonary and cardiac disease. [7].

5 January 2016 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
JHJennifer Harcourt
Jennifer Harcourt
MMMelissa McDonald
Melissa McDonald
PSPavel Svoboda
Pavel Svoboda
JPJan Pohl
Jan Pohl
KTKathleen Tatti
Kathleen Tatti
LSLia Haynes Smith
Lia Haynes Smith
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract illness in young children worldwide. Treatment options for severe RSV disease remain limited and the development of therapeutic treatment strategies remains a priority. LL-37, a small cationic host defense peptide involved in anti-inflammatory and anti-bacterial responses, reduces replication of or infection by multiple viruses, including influenza virus, in vitro, and protects against lethal challenge with influenza virus in vivo. LL-37 also protects against RSV infection of HEp-2 cells in vitro; however, HEp-2 are not reflective of polarized airway epithelial cells and respond differently to RSV infection. An air–liquid interface (ALI) Calu-3 model that more closely mimics the human airway epithelium was established. Using this in vitro model, the effectiveness of LL-37 in preventing RSV infection and replication was examined. LL-37, when pre-incubated with virus prior to RSV infection (prophylactic), significantly reduced the level of viral genome detected in infected Calu-3 cells, and decreased chemokine expression associated with RSV infection in vitro. In contrast, therapeutic treatment of RSV-infected ALI Calu-3 at 24 h and 3 days post-infection had minimal impact on RSV infection. Differences in the efficacy of LL-37 at reducing RSV infection under prophylactic and therapeutic conditions may in part be ascribed to differences in the method of peptide exposure. However, the efficacy of LL-37 at reducing RSV infection under prophylactic conditions indicates that further studies examining the efficacy of LL-37 as a small peptide inhibitor of RSV are warranted.

1 September 2005 in Journal of Virological Methods
Verified
Journal Article
Closed access
Ralph TrippRalph Tripp
Ralph Tripp
LSLia Haynes Smith
Lia Haynes Smith
DMDeborah Moore
Deborah Moore
BABarbara Anderson
Barbara Anderson
ATAzaibi Tamin
Azaibi Tamin
LALarry J. Anderson
Larry J. Anderson